Optimal DEtection of Atrial fibrillation in Transient Ischaemic Attack: Rationale and design of the ODEA-TIA trial - PubMed
5 hours ago
- #Atrial Fibrillation
- #Transient Ischaemic Attack
- #ECG Monitoring
- The ODEA-TIA trial is a multicentre, investigator-initiated, randomised, open-label, blinded-endpoint (PROBE) clinical trial.
- It aims to compare three ECG monitoring strategies for detecting atrial fibrillation (AF) in patients aged 50 years or older who experienced a TIA within 28 days before randomisation and had no prior history of AF.
- Participants are randomly assigned to undergo either 24-hour Holter ECG, 28-day non-invasive continuous ECG patch monitoring, or continuous recording with a subcutaneously implantable loop recorder for up to 2-years.
- The primary endpoint is the rate of newly detected AF within six months after study enrolment.
- Secondary endpoints include AF detection at 12 and 24 months, and overall prevalence of AF during follow-up in long-term recordings.
- Exploratory analyses include clinical outcomes, initiation of anticoagulation and performance parameters.
- A substudy investigates the usefulness of blood-based biomarkers to predict AF.
- The trial aims to establish evidence-based ECG monitoring strategies for detection of AF to improve secondary prevention in TIA patients.